Clinical Trial Update: Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing pembrolizumab plus lenvatinib to chemotherapy in endometrial cancer has completed with results posted in October 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer
• Endometrial Carcinoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• LENVIMA (lenvatinib)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Endometrial Neoplasms | Phase 3 | Status: COMPLETED | Results posted: 2024-10-16